CBSC: AI 评分 48/100 — AI 分析 (4月 2026)

Cardiac Biotech Solutions Inc. focuses on ambulatory non-invasive cardiac monitoring. The company provides FDA and CE cleared EKG devices, cloud-based software, and smartphone apps.

Key Facts: AI Score: 48/100 Sector: Healthcare

公司概况

概要：

Cardiac Biotech Solutions Inc. focuses on ambulatory non-invasive cardiac monitoring. The company provides FDA and CE cleared EKG devices, cloud-based software, and smartphone apps.

Cardiac Biotech Solutions Inc. delivers ambulatory non-invasive cardiac monitoring solutions, including FDA and CE cleared EKG devices and interactive software. Operating in the medical instruments and supplies sector, the company aims to improve patient compliance and provide accurate data to physicians through its international subsidiaries and My-Cardia (USA), Inc.

CBSC是做什么的？

Cardiac Biotech Solutions Inc. (CBSC) operates in the ambulatory non-invasive cardiac monitoring sector, providing products and services through its international subsidiaries. The company's core offerings include FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps compatible with both iOS and Android platforms. These solutions are designed to improve patient compliance for individuals at risk of abnormal heart rhythms and to provide physicians with more accurate diagnostic information. CBSC's wholly-owned U.S. subsidiary, My-Cardia (USA), Inc., is responsible for developing ECG recording devices that patients can wear in an ambulatory setting for up to 30 days. Cardiac Biotech Solutions Inc. focuses on innovation in the cardiac monitoring space, leveraging technology to enhance the accuracy and accessibility of diagnostic tools. The company's solutions cater to the growing need for remote patient monitoring and aim to streamline the process of cardiac data acquisition and analysis. With a focus on ambulatory settings, CBSC's products are designed to provide continuous monitoring without requiring patients to be confined to a hospital or clinic. The company's international presence allows it to serve a diverse range of markets and adapt its offerings to meet specific regional requirements. By combining hardware, software, and mobile applications, Cardiac Biotech Solutions Inc. seeks to offer a comprehensive solution for cardiac monitoring and diagnostics.

CBSC的投资论点是什么？

Cardiac Biotech Solutions Inc. presents a focused investment opportunity within the ambulatory cardiac monitoring space. With FDA and CE cleared EKG devices, the company addresses a critical need for remote and continuous cardiac monitoring. Key value drivers include the potential for increased adoption of its cloud-based software and smartphone apps, which enhance patient compliance and data accuracy. The company's gross margin stands at 43.3%. Growth catalysts include expanding its market reach through international subsidiaries and strategic partnerships. Potential risks involve competition from established players and the need for continuous innovation to maintain a competitive edge. The company's small size (5 employees) and OTC market listing introduce additional volatility and liquidity concerns. The negative P/E ratio of -3.60 and profit margin of -1767.1% indicate current financial challenges that require careful monitoring.

CBSC在哪个行业运营？

Cardiac Biotech Solutions Inc. operates within the medical instruments and supplies industry, which is experiencing growth due to the increasing prevalence of cardiovascular diseases and the demand for remote patient monitoring solutions. The market is competitive, with established players like CPIVF (CardioComm Solutions Inc.) and emerging companies vying for market share. Trends include the integration of AI and machine learning for improved diagnostics and the development of wearable devices for continuous monitoring. Cardiac Biotech Solutions Inc. aims to differentiate itself through its integrated hardware, software, and mobile app solutions.

Medical - Instruments & Supplies

Healthcare

CBSC有哪些增长机遇？

Expanding market reach through strategic partnerships: Cardiac Biotech Solutions Inc. can leverage partnerships with hospitals, clinics, and telehealth providers to expand its market reach and increase adoption of its cardiac monitoring solutions. The global telehealth market is projected to reach $55.6 billion by 2027, presenting a significant opportunity for CBSC to integrate its technology into remote patient care platforms. Timeline: Ongoing.
Developing advanced AI-powered diagnostic tools: Integrating artificial intelligence (AI) and machine learning (ML) algorithms into its cloud-based software can enhance the accuracy and efficiency of cardiac data analysis. The AI in healthcare market is expected to reach $34 billion by 2025, driven by the need for improved diagnostics and personalized treatment plans. CBSC can leverage AI to identify subtle patterns and anomalies in ECG data, providing physicians with valuable insights. Timeline: 1-2 years.
Focusing on geriatric care and remote monitoring: The aging population and the increasing prevalence of chronic diseases are driving the demand for remote patient monitoring solutions, particularly in geriatric care. Cardiac Biotech Solutions Inc. can tailor its products and services to meet the specific needs of elderly patients, such as ease of use and remote data transmission. The geriatric care market is projected to reach $1.04 trillion by 2028. Timeline: Ongoing.
Entering new geographic markets through international subsidiaries: Cardiac Biotech Solutions Inc. can leverage its international subsidiaries to expand its presence in emerging markets with high growth potential. These markets often have a greater need for affordable and accessible cardiac monitoring solutions. The Asia-Pacific medical device market is expected to grow at a CAGR of 8.8% from 2021 to 2028, presenting a significant opportunity for CBSC to establish a foothold in the region. Timeline: 2-3 years.
Enhancing mobile app functionality and user experience: Improving the functionality and user experience of its iOS and Android apps can drive greater patient engagement and compliance. This includes features such as personalized reminders, educational content, and seamless data sharing with healthcare providers. The mobile health (mHealth) market is projected to reach $254 billion by 2026, driven by the increasing adoption of smartphones and the growing demand for remote healthcare services. Timeline: 6-12 months.

FDA and CE cleared EKG devices provide a regulatory advantage in the ambulatory cardiac monitoring market.
Gross margin of 43.3% indicates potential for profitability with increased sales volume.
International subsidiaries enable market expansion and diversification of revenue streams.
Cloud-based acquisition software and smartphone apps enhance patient compliance and data accessibility.
My-Cardia (USA), Inc. subsidiary focuses on developing long-term ECG recording devices for ambulatory settings.

CBSC提供哪些产品和服务？

Develops and markets ambulatory non-invasive cardiac monitoring devices.
Offers FDA and CE cleared EKG devices for accurate heart rhythm monitoring.
Provides interactive cloud-based software for data acquisition and analysis.
Creates smartphone apps for iOS and Android platforms to enhance patient compliance.
Develops ECG recording devices worn by patients for up to 30 days.
Offers solutions for remote patient monitoring in ambulatory settings.
Focuses on improving the accuracy and accessibility of cardiac diagnostic tools.

CBSC如何赚钱？

Sells EKG devices and related hardware to healthcare providers and patients.
Offers subscription-based access to its cloud-based software platform.
Generates revenue through international subsidiaries in various markets.

Hospitals and clinics that require cardiac monitoring solutions.
Physicians who need accurate data for diagnosing heart rhythm abnormalities.
Patients at risk of abnormal heart rhythms who need remote monitoring.
Telehealth providers seeking to integrate cardiac monitoring into their services.

FDA and CE clearances provide a regulatory barrier to entry.
Proprietary cloud-based software and mobile apps offer a differentiated solution.
Established international subsidiaries provide a global distribution network.

什么因素可能推动CBSC股价上涨？

Upcoming: Potential partnerships with hospitals and clinics to expand market reach.
Upcoming: Development and launch of advanced AI-powered diagnostic tools.
Ongoing: Expansion into new geographic markets through international subsidiaries.
Ongoing: Increasing adoption of remote patient monitoring solutions in geriatric care.

CBSC的主要风险是什么？

Potential: Competition from established players in the cardiac monitoring market.
Potential: Regulatory changes and compliance requirements.
Potential: Technological advancements that could render existing products obsolete.
Ongoing: Limited financial disclosure and transparency due to OTC listing.
Ongoing: Negative P/E ratio and profit margin indicating financial challenges.

CBSC的核心优势是什么？

FDA and CE cleared EKG devices.
Interactive cloud-based acquisition software.
Smartphone apps for iOS and Android platforms.
Wholly-owned U.S. subsidiary, My-Cardia (USA), Inc.

CBSC的劣势是什么？

Small company size (5 employees).
Negative P/E ratio and profit margin.
OTC market listing with potential liquidity concerns.
Limited brand recognition compared to larger competitors.

CBSC有哪些机遇？

Expanding market reach through strategic partnerships.
Developing advanced AI-powered diagnostic tools.
Focusing on geriatric care and remote monitoring.
Entering new geographic markets through international subsidiaries.

CBSC面临哪些威胁？

Competition from established players in the cardiac monitoring market.
Regulatory changes and compliance requirements.
Technological advancements that could render existing products obsolete.
Economic downturns that could reduce healthcare spending.

CBSC的竞争对手是谁？

CardioComm Solutions Inc. — Offers similar ECG monitoring solutions with a focus on cloud-based data management. — (CPIVF)
Enzolytics, Inc. — Focuses on therapeutics, but may compete in overlapping diagnostic areas. — (ENZN)
Future Medical Development Corp. — Unknown differentiation due to limited information. — (FZMD)
Index Diagnostics, Inc. — Unknown differentiation due to limited information. — (IDXG)
LifeMD, Inc. — Provides telehealth services, potentially integrating cardiac monitoring. — (LIFD)

Key Metrics

MoonshotScore: 48/100

Company Profile

CEO: Charles K. Martin
Headquarters: Las Vegas, US
Employees: 5
Founded: 2016

AI Insight

AI analysis pending for CBSC

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Cardiac Biotech Solutions Inc. do?

Cardiac Biotech Solutions Inc. specializes in developing and marketing ambulatory non-invasive cardiac monitoring solutions. The company's core offerings include FDA and CE cleared EKG devices, interactive cloud-based software, and smartphone apps designed to improve patient compliance and provide accurate data to physicians. Through its U.S. subsidiary, My-Cardia (USA), Inc., CBSC develops ECG recording devices worn by patients for up to 30 days, enabling continuous monitoring in ambulatory settings. The company aims to enhance the accuracy and accessibility of cardiac diagnostic tools, catering to the growing demand for remote patient monitoring solutions.

What do analysts say about CBSC stock?

As of 2026-03-18, there is no available analyst coverage for Cardiac Biotech Solutions Inc. due to its OTC listing and small market capitalization. Key valuation metrics include a negative P/E ratio of -3.60 and a profit margin of -1767.1%, indicating current financial challenges. Growth considerations include the potential for increased adoption of its cardiac monitoring solutions and expansion into new markets. Investors should conduct their own due diligence and consider the risks associated with investing in OTC stocks before making any investment decisions.

What are the main risks for CBSC?

Cardiac Biotech Solutions Inc. faces several risks, including competition from established players in the cardiac monitoring market, regulatory changes and compliance requirements, and technological advancements that could render existing products obsolete. The company's OTC listing presents additional risks, such as limited financial disclosure, potential for price manipulation, and lower liquidity. The negative P/E ratio and profit margin indicate financial challenges that could impact the company's ability to sustain operations and invest in future growth. Investors should carefully consider these risks before investing in CBSC.